Section 338 elections
326
Securities and Exchange Commission (SEC)
75,
236
enforcement effectiveness
41
Securities Exchange Act of 1934
37–38t,
38
insider trading regulations
39–40
reporting requirements
38–39
Section 13, periodic reports
39
Section 14, proxy solicitations
39
Securities Investor Protection Corporation (SIPC)
484–485
Segmented capital markets
496
Selling entity, legal form of
297,
300
risk confronting, basic types of
Settlement tender offer, alternative takeover tactics
82f
Shareholder interest’s theory
76,
95–96
impact of leverage on return to
365,
366t
LBO shareholders, postbuyout returns to
363–364
LBO target firm (prebuyout) shareholders, prebuyout returns to
363
returns high for target shareholders
23–24
returns to acquirer shareholders
24–25
takeover defenses, impact of
leveraged recapitalizations and target firm financial returns
96
target firm shareholder financial returns
93–96
Short messaging system (SMS)
169
Single-firm recapitalizations
317
Small-scale merger exception
316
Social Security and Medicare taxes
268–269
Sovereign wealth funds (SWFs)
21,
503
Special purpose acquisition corporations (SPACs)
286
human resource management
459
nonlong-term debt liabilities, allocation of
459
separation and distribution agreement
460
tax matters agreement
460
M&A transactions, combined with
456–457
parent firm operating units, characteristics of
461,
461t
postannouncement financial returns
465–466
preannouncement abnormal returns
462t,
464
tax and accounting considerations
452
Squeeze-out/freeze-out merger
315
Staggered/classified board election
87
communication plan development
Statements of Financial Accounting Standards (SFAS)
339–340,
342
antitrust and securities laws
57
Step-transaction doctrine
326
Stock-for-assets deals
312
Stock-for-assets transaction
312
Stock-for-stock deals
312
Stock-for-stock purchase
312
acquirer transaction summary worksheet
383,
384t
constructing historical financials, and determining value drivers
building historical financial statements
389
collecting and analyzing historical data
388
normalizing historical data for forecasting purposes
388
pro forma financial statements
387–388
estimating synergy and investment required to
391
projecting Newco financials
391–394
selecting discount rate and terminal period assumptions to value Newco
395
offer price and posttransaction capital structure, determining appropriateness of
comparing offer price with estimated maximum offer price and comparable deals
396–397
comparing projected credit ratios with industry average ratios
397–398
Newco’s EPS, determining impact of deal on
398–401
Newco to meet/exceed required returns
401
projecting acquirer and targeting financials and estimating stand-alone values
389
Stocks, Bonds, Bills & Inflation
275
Stock subscription agreement
358
Strategic business units (SBUs)
161
Strategic realignment
6t,
9–10
Subordinated debentures
356
Surface Transportation Board (STB)
59
Surviving corporation
312
Sustainable growth value
192
operating/asset-related synergies
405–406
revenue-related synergy
404
T
Targeted customers, and potential for price discrimination
49
period cash flow statement
243,
246t
alternative tax structures
323
Section 338 elections
326
target assets, cash purchase of
324
target stock, cash purchase of
324
deductibility of interest expense
333
dividends received deduction
333
investments in capital
332
tax cut expectations and firm value
336
liabilities, minimizing
498
worldwide/global tax system
506–507
Tax-free cash-rich split-off
456
alternative tax-free reorganizations
326–329
1031 like-kind exchanges, arising from
329–331
target tax attributes treatment
329
Tax matters agreement
460
Tax Reform Act of 1986
60
Technological innovation
9–10
Technology objectives
111
Telecommunications Act (1996)
59
Terminal growth value
192
Thermo Fisher Scientific Inc.
409b
Time Warner Cable (TWC)
52
Total purchase price (PVTPP)
139–140
Toxic Substances Control Act of 1978
60
postannouncement financial returns
465–466
preannouncement abnormal returns
462t,
465
tax and accounting considerations
458
Transaction expenses (TE)
401
Transformational deals
155
Travel and entertainment (T&E) expenses
269
Treasury inflation-protected securities (TIPS)
510
Treasury stock method
400
Treaty on the Functioning of the European Union (TFEU)
61
Turnaround/defensive strategy
112
Typical business unit
116b
U
Uber Technologies Inc. (Uber)
283,
283b
Underperforming businesses
443,
462
Unemployment Compensation Act of 1992
60
Unfunded pension liabilities
107
United Nations Commission on International Trade Law (UNCITRAL)
477
United Technologies (UT)
204b
US Constitution authorizes Congress
477
US corporate tax rate
337
US Federal Drug Administration
307
US Foreign Corrupt Practices Act
37–38t,
58
US Securities and Exchange Commission
345–346
V
Valeant Pharmaceutical International Inc.
236
Valuable corporate asset
74
Valuation process, key steps
239–249
financial statements analyzation
239–243
historical data normalization
240
zero interest rate environment
254
Value chain, credit/debit card processing industry
122f
Value-enhancing investments
73–74,
95
Valuing private firms
268
applying valuation methodologies
272–273
asset-oriented approach
273
income/discounted cash flow, approach
272–273
relative value/market-based approach
273
replacement cost approach
273
externally generated information, lack of
267
firm-specific problems
267
internal controls and reporting systems, lack of
267
reported income manipulation, forms
267–268
control premiums, liquidity, and minority discounts
278–283
financial statements adjustment
268–271
Variable-growth (supernormal/nonconstant) valuation model
192–193,
194b
Voluntary liquidations
483
Voluntary out-of-court liquidation
478–479
W
Walgreens Boots Alliance
62b
Sections 13(D) and 13(G), ownership disclosure requirements
41–42
Sections 14(D), rules governing tender offer process
best price rule, 14(D)-10
42
obligations of acquirer
42
obligations of target firm
42
shareholder rights, 14(D)-4 to 14(D)-7
42
tender offers, regulation of
41
Worker Adjustment and Retraining Notification Act (WARN)
60
Working capital guarantee balance-sheet adjustments
304t
World Bank’s Multilateral Investment Guarantee Agency
504
World Health Organization (WHO)
231
X
Y
Z
Zero-growth valuation model
191,
191b